Fig. 2
The correlation between HMGB1 levels and the prognosis of GB patients treated with TMZ. A The mRNA levels of HMGB1 in non-tumor tissues (n = 14) and GB tissues (n = 528) from TCGA-GBM/HGU133 datasets (left panel), as well as in WHO II (n = 226), WHO III (n = 244) and WHO IV (n = 150) grade glioma tissues from TCGA-LGG/GBM datasets (right panel). B The overall survival (OS) rates of mRNA HMGB1low and HMGB1high GB patients from CGGA datasets (n = 489). C Representative immunohistochemistry (IHC) of HMGB1 in paired GB patients (left panel) with quantification (right panel). HMGB1 stains brown color. n = 41, Scale bars = 50 μm. D The concentration of HMGB1 in sera of paired GB patients. n = 41. E The OS rate of TMZ-treated serum HMGB1low and HMGB1high GB patients. n = 41. F Representative IHC of LC3B, SQSTM1, STX17 and HMGB1 in serial sections of GB specimens (GB7225 and GB1338) with TMZ treatment. Areas examined under higher magnification were marked. Brown color is positive. Scale bars = 50 μm. G The correlation between LC3B and HMGB1 expression in GB patients with TMZ treatment (n = 41) (upper panel). The correlation between SQSTM1 and HMGB1 expression in GB patients with TMZ treatment (n = 41) (lower panel). Pearson’s correlation test. *P < 0.05, **P < 0.01,***P < 0.001, ns = no significance